Nėra interneto ryšio – rodoma išsaugota puslapio versija.

Exelixis Inc

USUSD
← Į akcijų filtrą

Exelixis Inc (LSE:0IJO) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 3. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.

Apie įmonę

Svetainė
exelixis.com
Investuotojams
ir.exelixis.com/
Sektorius
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Būstinė
South San Francisco, United States
Generalinis direktorius
Dr. Michael M. Morrissey Ph.D.
Darbuotojai
1 077
Įkurta
1994
Apyvartoje esančios akcijos
247.78 mln. 2026-07-27 duomenimis
Laisvai apyvartinės akcijos
213.6 mln.
Rinkos kapitalizacija
14.36 mlrd. USD
Insaideriai
1.85%
Instituciniai investuotojai
106.81%
Šaka (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
US30161Q1040
LEI
254900PJQB59O2O95R37
Išmokų santykis
0%
FCF
1.17 mlrd. USD
Skola
0 USD
grynieji pinigai
Dividendų stažas
—
Pelnas, FCF ir dividendai – už 12 mėnesių iki 03.07.2026 (naujausia įmonės ataskaita).
Aprašymas

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Biržos ir tikeriai

BiržaTikerisValiutaKainaTipas
US USA StocksEXEL pagrindinisUSD59.02 +0.99%paprastosios akcijos
LSE London Stock Exchange0IJO IOBUSD59.69 +0.00%paprastosios akcijos
MI Borsa Italiana (Milan)1EXEL papildomasEUR52.01 -0.27%paprastosios akcijos

Kaina per 3 mėnesius

kilimo diena kritimo diena dividendų ex data išmokėjimo dataUžveskite / palieskite dieną — atidarymo, uždarymo, aukščiausia ir žemiausia kainos

Dividendai

Dividendų išmokų nerasta (patikrinta 10.10.2026). Įmonė greičiausiai nemoka dividendų.

Šios savaitės naujienos

Naujienų iš įmonės svetainės kol kas nėra.

reklama

Didžiausi akcininkai

TurėtojasDalisAkcijosAtaskaitos data
Blackrock Inc.11.73%29.08 mln.2026-06-30
Farallon Capital Managem…5.44%13.47 mln.2026-06-30
Renaissance Technologies…5.42%13.43 mln.2026-06-30
Vanguard Portfolio Manag…4.86%12.04 mln.2026-06-30
AQR Capital Management,…4.45%11.02 mln.2026-06-30
Vanguard Capital Managem…4.42%10.95 mln.2026-06-30
State Street Corporation4.02%9.97 mln.2026-06-30
Fuller & Thaler Asset Ma…3.6%8.93 mln.2026-06-30
iShares Trust-iShares Co…3.55%8.8 mln.2026-08-31
LSV Asset Management3.29%8.15 mln.2026-06-30
Geode Capital Management…3.09%7.65 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…3.06%7.58 mln.2026-06-30
Capitol Series Trust-Ful…2.84%7.04 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…2.21%5.47 mln.2026-06-30
MORRISSEY MICHAEL M (Chi…≈1.37%3.38 mln.2026-05-18
VANGUARD INDEX FUNDS-Van…1.27%3.16 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…1.16%2.88 mln.2026-06-30
Invesco Exchange-Traded…1.12%2.78 mln.2026-08-31
SPDR SERIES TRUST-State…0.8%1.99 mln.2026-08-31
SPDR S&P MIDCAP 400 ETF…0.74%1.84 mln.2026-08-31
iShares Trust-iShares Bi…0.74%1.82 mln.2026-08-31
PAPADOPOULOS STELIOS B (…≈0.48%1.2 mln.2026-05-27
SENNER CHRISTOPHER J. (C…≈0.39%955 0402026-05-18
HESSEKIEL JEFFREY J (Gen…≈0.28%694 3952025-05-15
AFTAB DANA T. (Officer)≈0.24%600 5762026-05-26
PETERSON AMY C (Officer)≈0.19%465 3932025-05-16
HALEY PATRICK JOSEPH (Of…≈0.14%357 6382026-05-20
WYSZOMIERSKI JACK L (Dir…≈0.11%284 3842026-06-01
POSTE GEORGE H (Director…≈0.05%127 1992026-05-27
JOHNSON DAVID EDWARD (Di…——2025-11-25